Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Carmat SA

Carmat SA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)1.39
  • Today's Change-0.226 / -13.95%
  • Shares traded515.22k
  • 1 Year change-69.96%
  • Beta1.2476
Data delayed at least 15 minutes, as of Sep 30 2024 10:14 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.

  • Revenue in EUR (TTM)5.53m
  • Net income in EUR-53.35m
  • Incorporated2008
  • Employees162.00
  • Location
    Carmat SA36avenue de l'Europe, Immeuble l'EtendardVELIZY VILLACOUBLAY 78140FranceFRA
  • Phone+33 139456450
  • Fax+33 139456451
  • Websitehttps://www.carmatsa.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Laboratoires Euromedis SA34.04m13.11m14.64m54.001.130.65831.100.43024.604.6011.667.930.64153.053.92630,347.6024.718.7634.6512.450.533815.5738.526.101.46-26.380.3031---37.18--320.97------
Theraclion SA1.82m-3.68m15.05m29.00--3.32--8.26-0.0811-0.08110.03970.12360.11180.10810.680762,835.52-22.54-32.98-30.99-48.0181.8860.85-201.68-249.162.86-40.630.2564--47.49-1.1325.97---7.23--
Intrasense SA3.31m-3.58m15.27m74.00--2.01--4.62-0.0697-0.06970.06440.13960.3897--4.0644,662.16-42.20-29.51-58.14-43.1289.0887.59-108.29-54.42---32.280.1697---12.801.53-4.65------
Ikonisys SA448.56k-2.27m16.51m10.00--1.02--36.81-0.233-0.2330.04611.620.02111.1832.2144,856.00-10.65---12.50---20.88---505.54--0.0619-29.680.1244---27.28--7.38------
Diagnostic Medical Systems SA42.15m-9.76m17.11m147.00--1.38--0.4059-0.4982-0.24812.230.70230.80271.816.81286,755.10-18.73-12.33-33.53-22.1437.5837.72-23.33-16.450.7105-3.520.5938--19.5111.62-106.30------
Mauna Kea Technologies SA10.48m-3.73m21.54m68.00------2.06-0.0578-0.05780.2126-0.28090.49052.312.45154,117.60-17.45-51.23-223.84-93.3033.6211.15-35.57-142.410.42874.292.38--40.139.1666.66---21.16--
Global Bioenergies SA486.33k-7.36m27.86m46.00------57.29-0.4036-0.40360.0267-0.00810.02762.740.118810,572.39-41.78-43.66-99.83-82.47-600.24-948.35-1,513.81-1,331.360.8447------365.8336.2527.78---19.49--
AbL Diagnostics SA5.61m54.36k44.40m19.00860.536.9061.967.910.00340.00340.34830.420.3703--1.42295,411.600.35873.240.58844.43----0.96858.811.87-47.510.3389---35.8474.86-95.08-49.30----
Biosynex SA92.98m-37.12m44.53m575.00--0.3482--0.4789-3.64-3.649.1011.920.37041.167.34161,700.90-14.1814.90-17.5119.4152.8451.92-38.3014.611.03-28.000.3459---52.7024.40-337.76------
Carmat SA5.53m-53.35m70.26m162.00------12.71-1.76-1.760.1787-0.64190.09321.611.2830,379.12-89.92-76.92-113.71-94.38-535.50---964.91-4,636.641.69-17.371.63--710.72---0.3502--16.99--
Affluent Medical SAS0.00-15.65m73.29m59.00--1.85-----0.5409-0.54090.001.020.00----0.00-26.83---31.42-------------24.430.328-------2.80------
Median Technologies SA22.23m-22.98m75.87m242.00------3.41-1.26-1.261.21-0.56080.6289-19.613.5591,842.98-65.02-54.57-186.81-157.51104.50101.57-103.40-93.701.40--2.21---6.1028.52-13.70--38.38--
Data as of Sep 30 2024. Currency figures normalised to Carmat SA's reporting currency: Euro EUR

Institutional shareholders

1.31%Per cent of shares held by top holders
HolderShares% Held
OFI Invest Asset Management SAas of 29 Feb 2024220.00k0.64%
La Fran�aise Asset Management SASas of 30 Apr 2024144.63k0.42%
Apo Asset Management GmbHas of 30 Sep 202366.00k0.19%
SSgA Funds Management, Inc.as of 03 Jul 202415.06k0.04%
Friedland Gestion SASas of 30 Apr 20246.85k0.02%
Financi�re Arbevel SAas of 30 Dec 20220.000.00%
Deka Investment GmbHas of 30 Nov 20230.000.00%
More ▼
Data from 31 Mar 2024 - 31 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.